Filters:
792 Projects | 546 Researchers | $372,728,064 Invested
2025
Sunbird Bio
Mario Morken, MS/MBA
Proof-of-Principal clinical study for blood based extracellular vesicle bound biomarker signatures quantifying brain alpha synuclein aggregation state
2025
Banner Health
Nicholas Ashton, PhD
Determining %p-tau217 and MTBR-243 by immunoassay
2024
MoCA Cognition
Ziad Nasreddine
Scientific validation of a digital MoCA for use in the general practice
2024
Johns Hopkins University
Philip Wong, PhD
Develop a diagnostic biomarker for frontotemporal dementia.
2024
Alamar Biosciences
Xiao-Jun Ma, PhD
Development of ARGO DX™ for a new generation of blood-based diagnostics for Alzheimer’s disease and related neurodegenerative diseases
2024
Polku Therapeutics
Timo Myöhänen, PhD
Novel prolyl oligopeptidase ligands to target Tau in frontotemporal dementia and other tauopathies
2024
Transposon Therapeutics
Andrew Satlin, MD
A Phase 2 Clinical Trial to Study the Effect of TPN-101, a Novel Nucleoside Reverse Transcriptase Inhibitor, in Patients with Alzheimer's Disease
2024
ViewMind
Yaakov Stern, PhD
Investigating ViewMind ocular digital cognitive biomarkers and their relationship to tau and amyloid PET scans.
2024
neotiv GmbH
David Berron, PhD
Integration of the neotiv digital cognitive assessments in the Swedish REAL AD study to screen and monitor preclinical Alzheimer’s disease
2024
NSC-Therapeutics GmbH
Manfred Windisch, PhD
A 2-Part, phase 2a, Multi-Center, randomised, double blinded, placebo controlled clinical trial investigating safety and tolerability, PK and exploratory efficacy of the M1 selective rigid, orthosteric M1 agonist NSC001 in patients suffering from mild to moderate Alzheimer’s Disease
View More